학술논문
MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
Document Type
Abstract
Author
Source
In Blood 15 November 2022 140 Supplement 1:7292-7293
Subject
Language
ISSN
0006-4971